About CVPath



In January 2016, Dr. Finn joined CVPath as its Medical Director and Chief of Research, and head of the Institute’s basic and translational research laboratory. At that time, he was also appointed Associate Professor of Medicine at the University of Maryland, where he serves (part-time) as a cardiologist and interventional cardiologist.

He has published over 100 peer-reviewed research articles, editorials, and reviews. He is an editorial board member of Coronary Artery Disease and of Arteriosclerosis, Thrombosis, and Vascular Biology.

Dr. Finn came to CVPath from Emory University in Atlanta where, from 2007 through 2015, he was Assistant Professor of Medicine and directed a basic and translational research laboratory with work funded by grants from the National Institutes of Health and the American Heart Association. His research interests are in the area of vascular biology, particularly human vascular disease. He has focused in particular on 1) the molecular mechanisms by which mTOR inhibitors delay endothelial recovery and function after vascular injury; 2) the role of alternative macrophage phenotypes in human atherosclerosis; and 3) mechanisms by which the macrophage scavenger receptor CD163 controls tissue regeneration after vascular injury.

He obtained his MD from Vanderbilt University in 2000. During medical school, he received a Howard Hughes Medical Student Research Fellowship and studied vascular gene therapy under David Dichek at the University of California at San Francisco. Dr. Finn did his internal medicine, cardiology and interventional cardiology training at the Massachusetts General Hospital in Boston, including two years of vascular biology research with Drs. Herman Gold and Rakesh Jain.